Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung ...

There are 182 clinical trials for Alzheimer’s treatments under way in 2025—an 11% increase on the previous year—testing 138 ...

SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Yelak Biru was diagnosed with multiple myeloma at 25 and given just a few years to live. Thirty years later, he's thriving.

Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

The U.S. saw more than 20,000 mpox cases and nearly six dozen deaths during the 2022 global mpox outbreak. San Francisco was ...

The head of the Food and Drug Administration has vowed to conduct a review of the abortion pill as the drug continues to be ...

EMJ spoke with Arnold Seto, a leading interventional cardiologist, to discuss innovations in vascular access, procedural ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...